Policy / Pricing FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results FDAThe U.S.Policy / PricingRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) FDA The U.S. Policy / PricingRead full story Post navigation Previous: USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concernsNext: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
